| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kousaku Mimura, Koji Kono, Takanori Maruyama, Mitsuaki Watanabe, Shinichiro Izawa, Shugo Shiba, Yoshiki Mizukami, Yoshihiko Kawaguchi, Masayuki Inoue, Tetsuo Kono, Aniruddha Choudhury, Rolf Kiessling, Hideki Fuji. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. International journal of cancer. vol 129. issue 10. 2011-11-04. PMID:21207425. |
lapatinib also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of her2 and egfr in escc cell lines. |
2011-11-04 |
2023-08-12 |
Not clear |
| Quanri Jin, Linda X Yuan, Delphine Boulbes, Jong Min Baek, Ying Nai Wang, Daniel Gomez-Cabello, David H Hawke, Sai Ching Yeung, Mong Hong Lee, Gabriel N Hortobagyi, Mien Chie Hung, Francisco J Estev. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast cancer research : BCR. vol 12. issue 6. 2011-09-12. PMID:21080941. |
lapatinib is a small-molecule tyrosine kinase inhibitor that blocks phosphorylation of the epidermal growth factor receptor and her2 in breast cancer cells, resulting in apoptosis. |
2011-09-12 |
2023-08-12 |
human |
| Sherry X Yang, Seth M Steinberg, Dat Nguyen, Sandra M Swai. p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. International journal of oncology. vol 38. issue 5. 2011-08-03. PMID:21399868. |
p53, her2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. |
2011-08-03 |
2023-08-12 |
Not clear |
| Sherry X Yang, Seth M Steinberg, Dat Nguyen, Sandra M Swai. p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. International journal of oncology. vol 38. issue 5. 2011-08-03. PMID:21399868. |
baseline p53, her2, tumor apoptosis, ki67, estrogen receptor (er), vegf-a, serum vegf (svegf), vegfr2-y951 and microvessel density (mvd) were prospectively designed and determined by immunohistochemistry and enzyme-linked immunosorbent assay. |
2011-08-03 |
2023-08-12 |
Not clear |
| Sherry X Yang, Seth M Steinberg, Dat Nguyen, Sandra M Swai. p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. International journal of oncology. vol 38. issue 5. 2011-08-03. PMID:21399868. |
our data suggest that baseline p53, apoptosis and her2 are each significantly associated with outcome in patients who received bevacizumab plus chemotherapy. |
2011-08-03 |
2023-08-12 |
Not clear |
| Annette Hayden, Peter W M Johnson, Graham Packham, Simon J Crab. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast cancer research and treatment. vol 127. issue 1. 2011-08-01. PMID:20556507. |
in conclusion, ahi induce growth inhibition, cell cycle arrest, apoptosis and differentiation in breast cancer cells and synergise with hdac and her2 inhibition. |
2011-08-01 |
2023-08-12 |
human |
| Radha Munagala, Farrukh Aqil, Ramesh C Gupt. Promising molecular targeted therapies in breast cancer. Indian journal of pharmacology. vol 43. issue 3. 2011-07-14. PMID:21713084. |
several other targeted agents currently under evaluation in preclinical and clinical trials include inhibitors of epidermal growth factor receptor (egfr), dual egfr and her2 inhibitors, vegf/vegfr inhibitors, and agents that interfere with crucial signaling pathways such as pi3k/akt/mtor and ras/mek/erk; agents against other tyrosine kinases such as src, insulin-like growth factor (igf)/igf-receptor (igfr); agents that promote apoptosis such as poly adp ribose polymerase inhibitors; agents that target invasion and metastasis such as matrix metalloproteinases inhibitors and others. |
2011-07-14 |
2023-08-12 |
human |
| Cristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Sílvia Cufí, Violeta Zenobia Torres-Garcia, Tamara Sauri-Nadal, Sonia Del Barco, Eugeni Lopez-Bonet, Joan Brunet, Begoña Martin-Castillo, Javier A Menende. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochemical and biophysical research communications. vol 407. issue 2. 2011-06-03. PMID:21402055. |
inhibitor of apoptosis (iap) survivin is indispensable for survival of her2 gene-amplified breast cancer cells with primary resistance to her1/2-targeted therapies. |
2011-06-03 |
2023-08-12 |
Not clear |
| Chuandong Ma, Xiuqing Niu, Jianmin Luo, Zhimin Shao, Kunwei She. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells. Cancer science. vol 101. issue 10. 2010-10-15. PMID:20701607. |
in the current study, we show that the combination of lapatinib and bortezomib results in a synergistic growth inhibition in human epidermal receptor 2 (her2)-overexpressing breast cancer cells and that the combination enhances apoptosis of sk-br-3 cells. |
2010-10-15 |
2023-08-12 |
human |
| Chuandong Ma, Xiuqing Niu, Jianmin Luo, Zhimin Shao, Kunwei She. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells. Cancer science. vol 101. issue 10. 2010-10-15. PMID:20701607. |
here, we showed that bortezomib notably induced apoptosis of lapatinib-resistant sk-br-3 pools and further inhibited her2 signaling in the resistant cells. |
2010-10-15 |
2023-08-12 |
human |
| Changfei Li, Sheng Cao, Zhen Liu, Xin Ye, Lizhao Chen, Songdong Men. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. International journal of cancer. vol 127. issue 7. 2010-09-13. PMID:20063318. |
the results showed that depletion of either her2 or upar by rna interference suppressed cell growth and induced cell apoptosis, but that these effects were significantly enhanced in cells depleted of both her2 and upar. |
2010-09-13 |
2023-08-12 |
Not clear |
| Ján Koval, Jaromír Mikes, Rastislav Jendzelovský, Martin Kello, Peter Solár, Peter Fedorock. Degradation of HER2 receptor through hypericin-mediated photodynamic therapy. Photochemistry and photobiology. vol 86. issue 1. 2010-08-27. PMID:19912559. |
combination with ag 825 resulted in increased apoptosis induction, total degradation of her2 and inhibition of colony formation. |
2010-08-27 |
2023-08-12 |
human |
| E A Mittendorf, Y Liu, S L Tucker, T McKenzie, N Qiao, S Akli, A Biernacka, Y Liu, L Meijer, K Keyomarsi, K K Hun. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. vol 29. issue 27. 2010-07-30. PMID:20453888. |
decreased her2 and lmw cyclin e expression had functional consequences, including decreased cyclin e-associated kinase activity and decreased proliferation, because of increased apoptosis and an increased accumulation of cells in the g1 phase. |
2010-07-30 |
2023-08-12 |
Not clear |
| Ranjita Banerjee, Ying Huang, James P McNamee, Margarita Todorova, Bertrand J Jean-Claud. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. The Journal of pharmacology and experimental therapeutics. vol 334. issue 1. 2010-07-13. PMID:20348204. |
6-(3-acetoxymethyl-3-methyltriazenyl)-4-(3'-bromophenylamino)quinazoline (rb24) showed significant antiproliferative activity against human breast cancer cells, and transfection of one such cell line, mda-mb-435, with erbb1 or erbb2 (her2) dramatically enhanced cell death by apoptosis. |
2010-07-13 |
2023-08-12 |
human |
| Robert Mallon, Irwin Hollander, Larry Feldberg, Judy Lucas, Veronica Soloveva, Aranapakam Venkatesan, Christoph Dehnhardt, Efren Delos Santos, Zecheng Chen, Osvaldo Dos Santos, Semiramis Ayral-Kaloustian, Jay Gibbon. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Molecular cancer therapeutics. vol 9. issue 4. 2010-07-07. PMID:20371716. |
in mda-mb-361 [breast: her2(+) and pik3ca mutant (e545k)], 30 nmol/l pki-402 induced cleaved poly(adp-ribose) polymerase (parp), a marker for apoptosis. |
2010-07-07 |
2023-08-12 |
human |
| Jene Choi, Soo Young Moon, Joon Pio Hong, Ji-young Song, Kyung Taek Oh, Sang-wook Le. Epidermal growth factor induces cell death in the absence of overexpressed epidermal growth factor receptor and ErbB2 in various human cancer cell lines. Cancer investigation. vol 28. issue 5. 2010-05-14. PMID:20073577. |
epidermal growth factor (egf) stimulates apoptosis in tumor cells depending on the expression levels of egf receptor and her2. |
2010-05-14 |
2023-08-12 |
human |
| I A Akimov, E L Chernolovskai. [The CCNB1, HER2, and PKC silencing induced by small interfering RNA decreases a division of different human cancer cells with interfering RNA decreases a different efficiency]. Molekuliarnaia biologiia. vol 44. issue 1. 2010-04-01. PMID:20198864. |
the her2, pkc, and ccnb1 gene silencing substantially reduced a growth rate of the cell lines, except hl-60, but did not affect the cell death and apoptosis. |
2010-04-01 |
2023-08-12 |
human |
| Saskia M Brachmann, Irmgard Hofmann, Christian Schnell, Christine Fritsch, Susan Wee, Heidi Lane, Shaowen Wang, Carlos Garcia-Echeverria, Sauveur-Michel Mair. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. vol 106. issue 52. 2010-02-17. PMID:20007781. |
specific apoptosis induction by the dual pi3k/mtor inhibitor nvp-bez235 in her2 amplified and pik3ca mutant breast cancer cells. |
2010-02-17 |
2023-08-12 |
Not clear |
| S Chandarlapaty, M Scaltriti, P Angelini, Q Ye, M Guzman, C A Hudis, L Norton, D B Solit, J Arribas, J Baselga, N Rose. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. vol 29. issue 3. 2010-02-12. PMID:19855434. |
chronic administration of hsp90 inhibitors in vivo results in sustained loss of her2 and p95-her2 expression and inhibition of akt activation, together with induction of apoptosis and complete inhibition of tumor growth in trastuzumab-resistant, p95-her2-overexpressing models. |
2010-02-12 |
2023-08-12 |
Not clear |
| Ivan Vannini, Wainer Zoli, Francesco Fabbri, Paola Ulivi, Anna Tesei, Silvia Carloni, Giovanni Brigliadori, Dino Amador. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anti-cancer drugs. vol 20. issue 10. 2009-12-29. PMID:19752719. |
simultaneous exposure to lapatinib and caelyx in skbr3 cell line produced an additive cytotoxic effect with dephosphorylation of her2 and egfr, an upregulation of p21, and an induction of apoptosis through dephosphorylation of bad and caspase cleavage. |
2009-12-29 |
2023-08-12 |
Not clear |